Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$124 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.3
Industry P/E
--
EV/EBITDA
0.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.5
Face value
--
Shares outstanding
70,957,600
CFO
$-278.14 Mln
EBITDA
$-438.53 Mln
Net Profit
$-394.44 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nkarta Inc (NKTX)
| -29.7 | 0.0 | 16.7 | -68.2 | -48.6 | -- | -- |
|
BSE Sensex*
| 5.7 | 1.2 | 6.1 | 7.0 | 16.2 | 18.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Nkarta Inc (NKTX)
| -62.0 | 10.2 | -61.0 | -75.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nkarta Inc (NKTX)
|
1.8 | 123.8 | 0.0 | -111.3 | -- | -27.5 | -- | 0.3 |
| 50.0 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.3 | 8,303.1 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 148.4 | 7,238.7 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 51.2 | 9,911.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 45.7 | 11,827.4 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.8 | 5.2 | |
| 53.9 | 6,506.1 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 315.3 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.8 | 9,927.7 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 128.2 | 12,449.9 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.8 | 4.9 |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural... killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Address: 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080 Read more
CEO, President & Director
Mr. Paul J. Hastings
CEO, President & Director
Mr. Paul J. Hastings
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Nkarta Inc (NKTX) stood at $ 489 Mln as on 31-Mar-25
The share price of Nkarta Inc (NKTX) is $1.75 (NASDAQ) as of 24-Jun-2025 16:00 EDT. Nkarta Inc (NKTX) has given a return of -48.59% in the last 3 years.
Nkarta Inc (NKTX) has a market capitalisation of $ 124 Mln as on 24-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Nkarta Inc (NKTX) is 0.33 times as on 24-Jun-2025, a 88% discount to its peers’ median range of 2.79 times.
Since, TTM earnings of Nkarta Inc (NKTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nkarta Inc (NKTX) and enter the required number of quantities and click on buy to purchase the shares of Nkarta Inc (NKTX).
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Address: 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080
The CEO & director of Mr. Paul J. Hastings. is Nkarta Inc (NKTX), and CFO & Sr. VP is Mr. Paul J. Hastings.
There is no promoter pledging in Nkarta Inc (NKTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Nkarta Inc (NKTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-27.48
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Nkarta Inc (NKTX) was $0 Mln.
$0.01
(
